More is less in CNS
Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its serotonin (5-HT1A) receptor agonist, which it is developing to treat generalized anxiety disorder.
Last week, the company reported that MN-305 missed the primary endpoint in a Phase II/III trial. The